Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations
- PMID: 25574106
- PMCID: PMC4284350
- DOI: 10.3748/wjg.v21.i1.311
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations
Abstract
Aim: To determine the mutation status of human telomerase reverse transcriptase gene (TERT) promoter region in hepatocellular carcinoma (HCC) from different geographical regions.
Methods: We analyzed the genomic DNA sequences of 59 HCC samples comprising 15 cell lines and 44 primary tumors, collected from patients living in Asia, Europe and Africa. We amplified a 474 bp DNA fragment of the promoter region of TERT gene including the 1295228 and 1295250 sequence of chromosome 5 by using PCR. Amplicons were then sequenced by Sanger technique and the sequence data were analyzed with by using DNADynamo software in comparison with wild type TERT gene sequence as a reference.
Results: The TERT mutations were found highly frequent in HCC. Eight of the fifteen tested cell lines displayed C228T mutation, and one had C250T mutation with a mutation frequency up to 60%. All of the mutations were heterozygous and mutually exclusive. Ten out of forty-four tumors displayed C228T mutation, and additional five tumors had C250T mutation providing evidence for mutation frequency of 34% in primary tumors. Considering the geographic origins of HCC tumors tested, TERT promoter mutation frequencies were higher in African (53%), when compared to non-African (24%) tumors (P = 0.056). There was also a weak inverse correlation between TERT promoter mutations and murine double minute 2 single nucleotide polymorphism 309 TG polymorphism (P = 0.058). Mutation frequency was nearly two times higher in established HCC cell lines (60%) compared to the primary tumors (34%).
Conclusion: TERT promoter is one of most frequent mutational targets in liver cancer, and hepatocellular carcinogenesis is highly associated with the loss of telomere-dependent cellular senescence control.
Keywords: Cellular immortality; Hepatocellular carcinoma; Liver cancer; Promoter mutation; Telomerase reverse transcriptase; Telomerase reverse transcriptase gene.
Figures


Similar articles
-
The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma.Oncotarget. 2017 Apr 4;8(14):23120-23129. doi: 10.18632/oncotarget.15498. Oncotarget. 2017. PMID: 28416747 Free PMC article.
-
The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.Oncotarget. 2016 Jan 5;7(1):684-99. doi: 10.18632/oncotarget.6331. Oncotarget. 2016. PMID: 26575952 Free PMC article.
-
Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.Hepatology. 2014 Dec;60(6):1983-92. doi: 10.1002/hep.27372. Epub 2014 Oct 27. Hepatology. 2014. PMID: 25123086
-
TERT promoter mutations in primary liver tumors.Clin Res Hepatol Gastroenterol. 2016 Feb;40(1):9-14. doi: 10.1016/j.clinre.2015.07.006. Epub 2015 Aug 31. Clin Res Hepatol Gastroenterol. 2016. PMID: 26336998 Review.
-
Geographic and Viral Etiology Patterns of TERT Promoter and CTNNB1 Exon 3 Mutations in Hepatocellular Carcinoma: A Comprehensive Review.Int J Mol Sci. 2025 Mar 22;26(7):2889. doi: 10.3390/ijms26072889. Int J Mol Sci. 2025. PMID: 40243493 Free PMC article. Review.
Cited by
-
Serum protein biomarkers for HCC risk prediction in HIV/HBV co-infected people: a clinical proteomic study using mass spectrometry.Front Immunol. 2023 Nov 10;14:1282469. doi: 10.3389/fimmu.2023.1282469. eCollection 2023. Front Immunol. 2023. PMID: 38022651 Free PMC article.
-
Direct comparison of the next-generation sequencing and iTERT PCR methods for the diagnosis of TERT hotspot mutations in advanced solid cancers.BMC Med Genomics. 2022 Feb 9;15(1):25. doi: 10.1186/s12920-022-01175-2. BMC Med Genomics. 2022. PMID: 35135543 Free PMC article.
-
Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications.Genes (Basel). 2016 Jul 18;7(7):38. doi: 10.3390/genes7070038. Genes (Basel). 2016. PMID: 27438857 Free PMC article. Review.
-
Telomere Maintenance Mechanisms in Cancer.Genes (Basel). 2018 May 3;9(5):241. doi: 10.3390/genes9050241. Genes (Basel). 2018. PMID: 29751586 Free PMC article. Review.
-
Exploring the Interplay of Telomerase Reverse Transcriptase and β-Catenin in Hepatocellular Carcinoma.Cancers (Basel). 2021 Aug 20;13(16):4202. doi: 10.3390/cancers13164202. Cancers (Basel). 2021. PMID: 34439356 Free PMC article. Review.
References
-
- Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15 Suppl 4:5–13. - PubMed
-
- Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol. 2013;10:34–42. - PubMed
-
- Ozen C, Yildiz G, Dagcan AT, Cevik D, Ors A, Keles U, Topel H, Ozturk M. Genetics and epigenetics of liver cancer. N Biotechnol. 2013;30:381–384. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous